Immunization of human hepatitis E viruses conferred protection against challenge by a camel hepatitis E virus

Dromedary camel hepatitis E virus is a novel HEV that belongs to the family Hepeviridae, and is classified as genotype 7 HEV (HEV-7). Since HEV-7 is transmitted from camels to humans and causes acute hepatitis E, this virus is a non-negligible pathogen for zoonosis, and a vaccine against HEV-7 infec...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2020-10, Vol.38 (46), p.7316-7322
Main Authors: Guo, Yingqiu, Yang, Fengmei, Xu, Xingli, Feng, Min, Liao, Yun, He, Zhanlong, Takeda, Naokazu, Muramatsu, Masamichi, Li, Qihan, Li, Tian-Cheng
Format: Article
Language:English
Subjects:
Adjuvants
Animal models
Animals
Antibodies
Antigens
Camels
Camelus
Cell culture
Dromedary camel hepatitis E virus
Experiments
Feces
Genomes
Genotypes
Hepatitis
Hepatitis E - prevention & control
Hepatitis E - veterinary
Hepatitis E virus
Hepeviridae
HEV-7
Humans
IgG antibody
Immunization
Immunoglobulin G
Infections
Laboratories
Membrane filters
Monkeys
Monkeys & apes
Pathogenesis
Proteins
Vaccination
Vaccine
Vaccines
Virus-like particle
Virus-like particles
Viruses
Zoonoses
Zoonotic infection
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dromedary camel hepatitis E virus is a novel HEV that belongs to the family Hepeviridae, and is classified as genotype 7 HEV (HEV-7). Since HEV-7 is transmitted from camels to humans and causes acute hepatitis E, this virus is a non-negligible pathogen for zoonosis, and a vaccine against HEV-7 infection is urgently needed. Here, we first intravenously inoculated HEV-7 to rhesus monkeys to explore the susceptibility, and we established an animal model. We then used virus-like particles (VLPs) of HEV-1 (HEV-1 VLPs) and HEV-3 (HEV-3 VLPs), a candidate hepatitis E vaccine, to intramuscularly inoculate rhesus monkeys. The monkeys elicited IgG antibody titers as high as >1:102,400 against heterologous HEV-7 without any adjuvants. The HEV-1 VLPs and HEV-3 VLPs-immunized monkeys were challenged intravenously with HEV-7, and they were protected completely from the infection, demonstrating that these VLPs could be a usable vaccine against HEV-7 infection. We also observed that HEV-7-infected rhesus monkeys did not show any liver damage during these experiments. Further efforts are necessary to establish an animal model for investigation of the pathogenesis of hepatitis E caused by HEV-7 infection.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2020.09.036